TuHURA Biosciences (HURA) Competitors

Xeris Biopharma (NASDAQ:XERS) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Does the media refer more to XERS or HURA?

In the previous week, TuHURA Biosciences had 2 more articles in the media than Xeris Biopharma. MarketBeat recorded 5 mentions for TuHURA Biosciences and 3 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.68 beat TuHURA Biosciences' score of 0.35 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
TuHURA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do institutionals & insiders have more ownership in XERS or HURA?

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by company insiders. Comparatively, 0.2% of TuHURA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is XERS or HURA more profitable?

TuHURA Biosciences has a net margin of 0.00% compared to Xeris Biopharma's net margin of -33.69%.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	-33.69%	N/A	-17.38%
TuHURA Biosciences	N/A	N/A	-152.88%

Do analysts prefer XERS or HURA?

Xeris Biopharma currently has a consensus price target of $6.10, indicating a potential upside of 33.48%. TuHURA Biosciences has a consensus price target of $12.67, indicating a potential upside of 235.10%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
TuHURA Biosciences	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Which has higher valuation and earnings, XERS or HURA?

TuHURA Biosciences has lower revenue, but higher earnings than Xeris Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$203.07M	3.52	-$62.26M	-$0.38	-12.03
TuHURA Biosciences	N/A	N/A	-$8.32M	N/A	N/A

Which has more volatility and risk, XERS or HURA?

Xeris Biopharma has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500.

Does the MarketBeat Community prefer XERS or HURA?

Xeris Biopharma received 143 more outperform votes than TuHURA Biosciences when rated by MarketBeat users. However, 100.00% of users gave TuHURA Biosciences an outperform vote while only 70.00% of users gave Xeris Biopharma an outperform vote.

Company	Underperform	Outperform
Xeris Biopharma	Outperform Votes 147 70.00%	Underperform Votes 63 30.00%
TuHURA Biosciences	Outperform Votes 4 100.00%	Underperform Votes No Votes

Summary

Xeris Biopharma beats TuHURA Biosciences on 8 of the 15 factors compared between the two stocks.